Cancer-associated fibroblasts as targets for immunotherapy

Immunotherapy

Volumn 4, Issue 11, 2012, Pages 1129-1138

  Kakarla, Sunitha ^a,b   Song, Xiao Tong ^a,b   Gottschalk, Stephen ^a,b  

^a CENTER FOR CELL AND GENE THERAPY   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

cancer associated fibroblasts; FAP directed therapies; fibroblast activation protein; immunotherapy; tumor microenvironment

Indexed keywords

BELAGENPUMATUCEL L; CALVASCULIN; CANCER VACCINE; DOXORUBICIN; FAP PROTEIN; FAP VACCINE; IMMUNOMODULATING AGENT; INCYCLINIDE; LEFLUNOMIDE; LY 2109761; MATRIX METALLOPROTEINASE; MONOCLONAL ANTIBODY; PLATELET DERIVED GROWTH FACTOR; SIBROTUZUMAB; SORAFENIB; SUNITINIB; TRANSFORMING GROWTH FACTOR BETA; TUMOR PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; BACKACHE; CANCER ASSOCIATED FIBROBLAST; CANCER CELL; CANCER IMMUNOTHERAPY; CANCER INVASION; CELL ACTIVATION; CELL FUNCTION; DRUG TARGETING; FIBROBLAST; HUMAN; IMMUNOMODULATION; METASTASIS; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW; TUMOR GROWTH; TUMOR MICROENVIRONMENT;

ANIMALS; CELL COMMUNICATION; FIBROBLASTS; HUMANS; IMMUNOTHERAPY; NEOPLASMS; TUMOR MICROENVIRONMENT;

EID: 84870462491     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.12.112     Document Type: Review

References (108)

1. Paget S. The distribution of secondary growth in cancer of the breast. Lancet 1, 571-573 (1889).
2. Mueller MM, Fusenig NE. Friends or foes-bipolar effects of the tumour stroma in cancer. Nat. Rev. Cancer 4(11), 839-849 (2004).
3. De WO, Demetter P, Mareel M, Bracke M. Stromal myofibroblasts are drivers of invasive cancer growth. Int. J. Cancer 123(10), 2229-2238 (2008).
4. Krtolica A, Parrinello S, Lockett S, Desprez PY, Campisi J. Senescent fibroblasts promote epithelial cell growth and tumorigenesis: a link between cancer and aging. Proc. Natl Acad. Sci. USA 98(21), 12072-12077 (2001).
5. Gonda TA, Tu S, Wang TC. Chronic inflammation, the tumor microenvironment and carcinogenesis. Cell Cycle. 8(13), 2005-2013 (2009).
6. Kurose K, Gilley K, Matsumoto S, Watson PH, Zhou XP, Eng C. Frequent somatic mutations in PTEN and TP53 are mutually exclusive in the stroma of breast carcinomas. Nat. Genet. 32(3), 355-357 (2002).
7. Hill R, Song Y, Cardiff RD, van Dyke T. Selective evolution of stromal mesenchyme with p53 loss in response to epithelial tumorigenesis. Cell 123(6), 1001-1011 (2005).
8. Hu M, Yao J, Cai L et al. Distinct epigenetic changes in the stromal cells of breast cancers. Nat. Genet. 37(8), 899-905 (2005).
9. Radisky DC, Kenny PA, Bissell MJ. Fibrosis and cancer: do myofibroblasts come also from epithelial cells via EMT? J. Cell. Biochem. 101(4), 830-839 (2007).
10. Zeisberg EM, Potenta S, Xie L, Zeisberg M, Kalluri R. Discovery of endothelial to mesenchymal transition as a source for carcinoma-associated fibroblasts. Cancer Res. 67(21), 10123-10128 (2007).
11. Direkze NC, Hodivala-Dilke K, Jeffery R et al. Bone marrow contribution to tumor-associated myofibroblasts and fibroblasts. Cancer Res. 64(23), 8492-8495 (2004).
12. Wipff PJ, Rifkin DB, Meister JJ, Hinz B. Myofibroblast contraction activates latent TGF-b1 from the extracellular matrix. J. Cell. Biol. 179(6), 1311-1323 (2007).
13. Leask A, Abraham DJ. TGF-b signaling and the fibrotic response. FASEB J. 18(7), 816-827 (2004).
14. Powell DW, Adegboyega PA, Di Mari JF, Mifflin RC. Epithelial cells and their neighbors I. Role of intestinal myofibroblasts in development, repair, and cancer. Am. J. Physiol. Gastrointest. Liver Physiol. 289(1), G2-G7 (2005).
15. Ostman A, Heldin CH. PDGF receptors as targets in tumor treatment. Adv. Cancer Res. 97, 247-274 (2007).
16. Spaeth EL, Dembinski JL, Sasser AK et al. Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression. PLoS One 4(4), e4992 (2009).
17. Iwano M, Plieth D, Danoff TM, Xue C, Okada H, Neilson EG. Evidence that fibroblasts derive from epithelium during tissue fibrosis. J. Clin. Invest. 110(3), 341-350 (2002).
18. Faouzi S, Le BB, Neaud V et al. Myofibroblasts are responsible for collagen synthesis in the stroma of human hepatocellular carcinoma: an in vivo and in vitro study. J. Hepatol. 30(2), 275-284 (1999).
19. Serini G, Bochaton-Piallat ML, Ropraz P et al. The fibronectin domain ED-A is crucial for myofibroblastic phenotype induction by transforming growth factor-b1. J. Cell. Biol. 142(3), 873-881 (1998).
20. Chang HY, Chi JT, Dudoit S et al. Diversity, topographic differentiation, and positional memory in human fibroblasts. Proc. Natl Acad. Sci. USA 99(20), 12877-12882 (2002).
21. Grugan KD, Miller CG, Yao Y et al. Fibroblast-secreted hepatocyte growth factor plays a functional role in esophageal squamous cell carcinoma invasion. Proc. Natl Acad. Sci. USA 107(24), 11026-11031 (2010).
22. Li G, Satyamoorthy K, Herlyn M. N-cadherin-mediated intercellular interactions promote survival and migration of melanoma cells. Cancer Res. 61(9), 3819-3825 (2001).
23. Franco OE, Jiang M, Strand DW et al. Altered TGF-b signaling in a subpopulation of human stromal cells promotes prostatic carcinogenesis. Cancer Res. 71(4), 1272-1281 (2011).
24. Rudnick JA, Arendt LM, Klebba I et al. Functional heterogeneity of breast fibroblasts is defined by a prostaglandin secretory phenotype that promotes expansion of cancer-stem like cells. PLoS One 6(9), e24605 (2011).
25. Skobe M, Fusenig NE. Tumorigenic conversion of immortal human keratinocytes through stromal cell activation. Proc. Natl Acad. Sci. USA 95(3), 1050-1055 (1998).
26. Tjomsland V, Spangeus A, Valila J et al. Interleukin 1a sustains the expression of inflammatory factors in human pancreatic cancer microenvironment by targeting cancer-associated fibroblasts. Neoplasia 13(8), 664-675 (2011).
27. Hugo HJ, Lebret S, Tomaskovic-Crook E et al. Contribution of fibroblast and mast cell (afferent) and tumor (efferent) IL-6 effects within the tumor microenvironment. Cancer Microenviron. 5(1), 83-93 (2012).
28. Hynes RO. The extracellular matrix: not just pretty fibrils. Science 326(5957), 1216-1219 (2009).
29. Erez N, Truitt M, Olson P, Arron ST, Hanahan D. Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-kB-dependent manner. Cancer Cell 17(2), 135-147 (2010).
30. Orimo A, Gupta PB, Sgroi DC et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 121(3), 335-348 (2005).
31. Fukumura D, Xavier R, Sugiura T et al. Tumor induction of VEGF promoter activity in stromal cells. Cell 94(6), 715-725 (1998).
32. Crawford Y, Kasman I, Yu L et al. PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. Cancer Cell 15(1), 21-34 (2009).
33. Powathil G, Kohandel M, Milosevic M, Sivaloganathan S. Modeling the spatial distribution of chronic tumor hypoxia: implications for experimental and clinical studies. Comput. Math. Methods Med. 2012, 410602-(2012).
34. Pavlides S, Tsirigos A, Migneco G et al. The autophagic tumor stroma model of cancer: role of oxidative stress and ketone production in fueling tumor cell metabolism. Cell Cycle 9(17), 3485-3505 (2010).
35. Cannito S, Novo E, Compagnone A et al. Redox mechanisms switch on hypoxia-dependent epithelial-mesenchymal transition in cancer cells. Carcinogenesis 29(12), 2267-2278 (2008).
36. Taub DD, Turcovski-Corrales SM, Key ML, Longo DL, Murphy WJ. Chemokines and T lymphocyte activation: I. b chemokines costimulate human T lymphocyte activation in vitro. J. Immunol. 156(6), 2095-2103 (1996).
37. Sturm A, Krivacic K A, Fiocchi C, Levine AD. Dual function of the extracellular matrix: stimulatory for cell cycle progression of naive T cells and antiapoptotic for tissue-derived memory T cells. J. Immunol. 173(6), 3889-3900 (2004).
38. Barnas JL, Simpson-Abelson MR, Yokota SJ, Kelleher RJ, Bankert RB. T cells and stromal fibroblasts in human tumor microenvironments represent potential therapeutic targets. Cancer Microenviron. 3(1), 29-47 (2010).
39. Liao D, Luo Y, Markowitz D, Xiang R, Reisfeld R A. Cancer associated fibroblasts promote tumor growth and metastasis by modulating the tumor immune microenvironment in a 4T1 murine breast cancer model. PLoS One 4(11), e7965 (2009).
40. Chomarat P, Banchereau J, Davoust J, Palucka AK. IL-6 switches the differentiation of monocytes from dendritic cells to macrophages. Nat. Immunol. 1(6), 510-514 (2000).
41. Protti MP, De ML. Cross-talk within the tumor microenvironment mediates Th2-type inflammation in pancreatic cancer. Oncoimmunology 1(1), 89-91 (2012).
42. Shojaei F, Zhong C, Wu X, Yu L, Ferrara N. Role of myeloid cells in tumor angiogenesis and growth. Trends Cell. Biol. 18(8), 372-378 (2008).
43. Nizar S, Meyer B, Galustian C, Kumar D, Dalgleish A. T regulatory cells, the evolution of targeted immunotherapy. Biochim. Biophys. Acta 1806(1), 7-17 (2010).
44. Munn DH, Mellor AL. Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J. Clin. Invest. 117(5), 1147-1154 (2007).
45. Pinchuk IV, Saada JI, Beswick EJ et al. PD-1 ligand expression by human colonic myofibroblasts/fibroblasts regulates CD4+ T-cell activity. Gastroenterology 135(4), 1228-1237, 1237 (2008).
46. Chen CH, Seguin-Devaux C, Burke NA et al. Transforming growth factor b blocks Tec kinase phosphorylation, Ca2+ influx, and NFATc translocation causing inhibition of T cell differentiation. J. Exp. Med. 197(12), 1689-1699 (2003).
47. Nazareth MR, Broderick L, Simpson-Abelson MR, Kelleher RJ, Yokota SJ, Bankert RB. Characterization of human lung tumor-associated fibroblasts and their ability to modulate the activation of tumor-associated T cells. J. Immunol. 178(9), 5552-5562 (2007).
48. Balsamo M, Scordamaglia F, Pietra G et al. Melanoma-associated fibroblasts modulate NK cell phenotype and antitumor cytotoxicity. Proc. Natl Acad. Sci. USA 106(49), 20847-20852 (2009).
49. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer 2(3), 161-174 (2002).
50. Toullec A, Gerald D, Despouy G et al. Oxidative stress promotes myofibroblast differentiation and tumour spreading. EMBO Mol. Med. 2(6), 211-230 (2010).
51. Marastoni S, Ligresti G, Lorenzon E, Colombatti A, Mongiat M. Extracellular matrix: a matter of life and death. Connect. Tissue Res. 49(3), 203-206 (2008).
52. Kanayama S, Yamada Y, Kawaguchi R, Tsuji Y, Haruta S, Kobayashi H. Hepatocyte growth factor induces anoikis resistance by up-regulation of cyclooxygenase-2 expression in uterine endometrial cancer cells. Oncol. Rep. 19(1), 117-122 (2008).
53. Gaggioli C, Hooper S, Hidalgo-Carcedo C et al. Fibroblast-led collective invasion of carcinoma cells with differing roles for RhoGTPases in leading and following cells. Nat. Cell. Biol. 9(12), 1392-1400 (2007).
54. Mani SA, Guo W, Liao MJ et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133(4), 704-715 (2008).
55. Stuelten CH, Busch JI, Tang B et al. Transient tumor-fibroblast interactions increase tumor cell malignancy by a TGF-b mediated mechanism in a mouse xenograft model of breast cancer. PLoS One 5(3), e9832 (2010).
56. Boyd NF, Guo H, Martin LJ et al. Mammographic density and the risk and detection of breast cancer. N. Engl. J. Med. 356(3), 227-236 (2007).
57. Cohen SJ, Alpaugh RK, Palazzo I et al. Fibroblast activation protein and its relationship to clinical outcome in pancreatic adenocarcinoma. Pancreas 37(2), 154-158 (2008).
58. Shi M, Yu DH, Chen Y et al. Expression of fibroblast activation protein in human pancreatic adenocarcinoma and its clinicopathological significance. World J. Gastroenterol. 18(8), 840-846 (2012).
59. Fujita H, Ohuchida K, Mizumoto K et al. a-smooth muscle actin expressing stroma promotes an aggressive tumor biology in pancreatic ductal adenocarcinoma. Pancreas 39(8), 1254-1262 (2010).
60. Schoppmann SF, Berghoff A, Dinhof C et al. Podoplanin-expressing cancer-associated fibroblasts are associated with poor prognosis in invasive breast cancer. Breast Cancer Res. Treat. 134(1), 237-244 (2012).
61. Spiotto MT, Rowley DA, Schreiber H. Bystander elimination of antigen loss variants in established tumors. Nat. Med. 10(3), 294-298 (2004).
62. Zhang B, Bowerman NA, Salama JK et al. Induced sensitization of tumor stroma leads to eradication of established cancer by T cells. J. Exp. Med. 204(1), 49-55 (2007).
63. Sethi T, Rintoul RC, Moore SM et al. Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo. Nat. Med. 5(6), 662-668 (1999).
64. Heldin CH, Rubin K, Pietras K, Ostman A. High interstitial fluid pressure-an obstacle in cancer therapy. Nat. Rev. Cancer 4(10), 806-813 (2004).
65. Brown JM, Giaccia AJ. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res. 58(7), 1408-1416 (1998).
66. Liang D, Ma Y, Liu J et al. The hypoxic microenvironment upgrades stem-like properties of ovarian cancer cells. BMC Cancer 12, 201-(2012).
67. Fassnacht M, Lee J, Milazzo C et al. Induction of CD4+ and CD8+ T-cell responses to the human stromal antigen, fibroblast activation protein: implication for cancer immunotherapy. Clin. Cancer Res. 11(15), 5566-5571 (2005).
68. Ostman A, Augsten M. Cancer-associated fibroblasts and tumor growth-bystanders turning into key players. Curr. Opin. Genet. Dev. 19(1), 67-73 (2009).
69. Rettig WJ, Garin-Chesa P, Beresford HR, Oettgen HF, Melamed MR, Old LJ. Cell-surface glycoproteins of human sarcomas: differential expression in normal and malignant tissues and cultured cells. Proc. Natl Acad. Sci. USA 85(9), 3110-3114 (1988).
70. Rettig WJ, Su SL, Fortunato SR et al. Fibroblast activation protein: purification, epitope mapping and induction by growth factors. Int. J. Cancer 58(3), 385-392 (1994).
71. Park JE, Lenter MC, Zimmermann RN, Garin-Chesa P, Old LJ, Rettig WJ. Fibroblast activation protein, a dual specificity serine protease expressed in reactive human tumor stromal fibroblasts. J. Biol. Chem. 274(51), 36505-36512 (1999).
72. Garin-Chesa P, Old LJ, Rettig WJ. Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. Proc. Natl Acad. Sci. USA 87(18), 7235-7239 (1990).
73. Kelly T. Fibroblast activation protein-a and dipeptidyl peptidase IV (CD26): cell-surface proteases that activate cell signaling and are potential targets for cancer therapy. Drug Res. Updat. 8(1-2), 51-58 (2005).
74. Chen WT, Kelly T. Seprase complexes in cellular invasiveness. Cancer Metastasis Rev. 22(2-3), 259-269 (2003).
75. Brennen WN, Isaacs JT, Denmeade SR. Rationale behind targeting fibroblast activation protein-expressing carcinoma-associated fibroblasts as a novel chemotherapeutic strategy. Mol. Cancer Ther. 11(2), 257-266 (2012).
76. Cheng JD, Valianou M, Canutescu AA et al. Abrogation of fibroblast activation protein enzymatic activity attenuates tumor growth. Mol. Cancer Ther. 4(3), 351-360 (2005).
77. Kraman M, Bambrough PJ, Arnold JN et al. Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-a. Science 330(6005), 827-830 (2010).
78. Santos AM, Jung J, Aziz N, Kissil JL, Pure E. Targeting fibroblast activation protein inhibits tumor stromagenesis and growth in mice. J. Clin. Invest. 119(12), 3613-3625 (2009).
79. LeBeau AM, Brennen WN, Aggarwal S, Denmeade SR. Targeting the cancer stroma with a fibroblast activation protein-activated promelittin protoxin. Mol. Cancer Ther. 8(5), 1378-1386 (2009).
80. Welt S, Divgi CR, Scott AM et al. Antibody targeting in metastatic colon cancer: a Phase I study of monoclonal antibody F19 against a cell-surface protein of reactive tumor stromal fibroblasts. J. Clin. Oncol. 12(6), 1193-1203 (1994).
81. Scott AM, Wiseman G, Welt S et al. A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin. Cancer Res. 9(5), 1639-1647 (2003).
82. Tanswell P, Garin-Chesa P, Rettig WJ et al. Population pharmacokinetics of antifibroblast activation protein monoclonal antibody F19 in cancer patients. Br. J. Clin. Pharmacol. 51(2), 177-180 (2001).
83. Ostermann E, Garin-Chesa P, Heider KH et al. Effective immunoconjugate therapy in cancer models targeting a serine protease of tumor fibroblasts. Clin. Cancer Res. 14(14), 4584-4592 (2008).
84. Wuest T, Gerlach E, Banerjee D, Gerspach J, Moosmayer D, Pfizenmaier K. TNF-selectokine: a novel prodrug generated for tumor targeting and site-specific activation of tumor necrosis factor. Oncogene 21(27), 4257-4265 (2002).
85. Messerschmidt SK, Musyanovych A, Altvater M et al. Targeted lipid-coated nanoparticles: delivery of tumor necrosis factor-functionalized particles to tumor cells. J. Control. Release 137(1), 69-77 (2009).
86. Samel D, Muller D, Gerspach J et al. Generation of a FasL-based proapoptotic fusion protein devoid of systemic toxicity due to cell-surface antigen-restricted activation. J. Biol. Chem. 278(34), 32077-32082 (2003).
87. Burckhart T, Thiel M, Nishikawa H et al. Tumor-specific crosslinking of GITR as costimulation for immunotherapy. J. Immunother. 33(9), 925-934 (2010).
88. Lee J, Fassnacht M, Nair S, Boczkowski D, Gilboa E. Tumor immunotherapy targeting fibroblast activation protein, a product expressed in tumor-associated fibroblasts. Cancer Res. 65(23), 11156-11163 (2005).
89. Loeffler M, Kruger JA, Niethammer AG, Reisfeld RA. Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake. J. Clin. Invest. 116(7), 1955-1962 (2006).
90. Wen Y, Wang CT, Ma TT et al. Immunotherapy targeting fibroblast activation protein inhibits tumor growth and increases survival in a murine colon cancer model. Cancer Sci. 101(11), 2325-2332 (2010).
91. Sadelain M, Riviere I, Brentjens R. Targeting tumours with genetically enhanced T lymphocytes. Nat. Rev. Cancer 3(1), 35-45 (2003).
92. Kakarla S, Wang L, Rowley D, Pfizenmaier K, Gottschalk S. Improving T-cell immunotherapies for solid tumors by targeting the tumor stroma. Biol. Blood Marrow Trans. 17(2 Suppl. 1), S270 (2011).
93. Kobayashi T, Liu X, Wen FQ et al. Smad3 mediates TGF-b1 induction of VEGF production in lung fibroblasts. Biochem. Biophys. Res. Commun. 327(2), 393-398 (2005).
94. Chen MM, Lam A, Abraham JA, Schreiner GF, Joly AH. CTGF expression is induced by TGF-b in cardiac fibroblasts and cardiac myocytes: a potential role in heart fibrosis. J. Mol. Cell. Cardiol. 32(10), 1805-1819 (2000).
95. Yingling JM, Blanchard KL, Sawyer JS. Development of TGF-b signalling inhibitors for cancer therapy. Nat. Rev. Drug Discov. 3(12), 1011-1022 (2004).
96. Fakhrai H, Dorigo O, Shawler DL et al. Eradication of established intracranial rat gliomas by transforming growth factor b antisense gene therapy. Proc. Natl Acad. Sci. USA 93(7), 2909-2914 (1996).
97. Nemunaitis J, Dillman RO, Schwarzenberger PO et al. Phase II study of belagenpumatucel-L, a transforming growth factor b-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer. J. Clin. Oncol. 24(29), 4721-4730 (2006).
98. Flechsig P, Dadrich M, Bickelhaupt S et al. LY2109761 attenuates radiation-induced pulmonary murine fibrosis via reversal of TGF-b and BMP associated proinflammatory and proangiogenic signals. Clin. Cancer Res. 18(13), 3616-3627 (2012).
99. Akhurst RJ. TGF-b antagonists: why suppress a tumor suppressor? J. Clin. Invest. 109(12), 1533-1536 (2002).
100. Akhurst RJ. TGF b signaling in health and disease. Nat. Genet. 36(8), 790-792 (2004).
101. Bollard CM, Rossig C, Calonge MJ et al. Adapting a transforming growth factor b-related tumor protection strategy to enhance antitumor immunity. Blood 99(9), 3179-3187 (2002).
102. Lacuesta K, Buza E, Hauser H et al. Assessing the safety of cytotoxic T lymphocytes transduced with a dominant negative transforming growth factor-b receptor. J. Immun. 29(3), 250-260 (2006).
103. Yu Q, Stamenkovic I. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-b and promotes tumor invasion and angiogenesis. Genes Dev. 14(2), 163-176 (2000).
104. Hidalgo M, Eckhardt SG. Development of matrix metalloproteinase inhibitors in cancer therapy. J. Natl Cancer Inst. 93(3), 178-193 (2001).
105. Steeghs N, Nortier JW, Gelderblom H. Small molecule tyrosine kinase inhibitors in the treatment of solid tumors: an update of recent developments. Ann. Surg. Oncol. 14(2), 942-953 (2007).
106. Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 356(2), 125-134 (2007).
107. Vanneman M, Dranoff G. Combining immunotherapy and targeted therapies in cancer treatment. Nat. Rev. Cancer 12(4), 237-251 (2012).
108. Shrimali RK, Yu Z, Theoret MR, Chinnasamy D, Restifo NP, Rosenberg SA. Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res. 70(15), 6171-6180 (2010).